Astrazeneca plc AZN.US 總覽分析
)AZN 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分優異，股利評分名列前茅，值得長期累積部位。若想獲得較好的進場時機，可參考技術面趨勢與波段評分
AZN 近期報酬表現
2.74%
Astrazeneca plc
3.56%
同產業平均
1.47%
S&P500
與 AZN 同產業的標的表現
- NVS Novartis ag價值 4 分趨勢 4 分波段 4 分籌碼 2 分股利 5 分查看更多
AZN 公司資訊
AstraZeneca PLC is a science-led biopharmaceutical company. It discovers, develops, and commercializes prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its biopharmaceuticals products include Farxiga, Crestor, Breztri and others. Its investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus. Its oncology candidate includes FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer, which is in a Phase II trial. It also discovers, develops, and manufactures T-cell receptor therapies. Its Eneboparatide is an investigational therapeutic peptide.